Vivos Therapeutics Shares More than Double on FDA's 510(k) Clearance for Sleep Apnea Treatment

By Denny Jacob

Vivos Therapeutics shares more than doubled following 510(k) clearance from the U.S. Food and Drug Administration for treating severe obstructive sleep apnea using its oral appliances.

The stock, which rose 169% to $11.80 in early trading Wednesday, is up 15% on the year so far.

The medical device and technology company said the clearance applied to its removable complete airway repositioning and/or expansion oral devices. It added that it is the first company to ever have approved and bring to market a clear alternative treatment to CPAP or surgical neurostimulation implants for patients with severe obstructive sleep apnea as a result of the clearance.

Write to Denny Jacob at [e-mail]

(END) Dow Jones Newswires

11-29-23 1040ET